Nanostructured lipid carriers: Promising drug delivery systems for future clinics

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 1, 2016, Pages 143-161

  Beloqui, Ana ^a   Solinís, María Ángeles ^b   Rodríguez Gascón, Alicia ^b   Almeida, António J ^c   Préat, Véronique ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Lipid nanoparticles; Nanostructured lipid carriers; NLC; SLN

Indexed keywords

NANOPARTICLES; TRANSPORTATION ROUTES;

CLINICAL SETTINGS; CONTROLLED DRUG DELIVERY SYSTEMS; DRUG DELIVERY SYSTEM; LIPID NANOPARTICLES; NANOSTRUCTURED LIPID CARRIER (NLC); NANOSTRUCTURED LIPID CARRIERS; STATE OF THE ART; TECHNOLOGICAL PROCESS;

CONTROLLED DRUG DELIVERY;

DRUG CARRIER; FLUORESCENT DYE; LIPID; NANOCARRIER; NANOPARTICLE; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG; LIPOSOME; NANOCAPSULE;

CHEMICAL COMPOSITION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; HOSPITAL; HUMAN; INFLAMMATORY BOWEL DISEASE; LUNG CANCER; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; REVIEW; STRATUM CORNEUM; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY; DIFFUSION; FORECASTING; NANOMEDICINE; TRENDS; ULTRASTRUCTURE;

DIFFUSION; FORECASTING; LIPIDS; LIPOSOMES; NANOCAPSULES; NANOMEDICINE;

EID: 84952942293     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.09.004     Document Type: Review

References (176)

1. Müller R.H., Mäde K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000, 50:161-177.
2. Müller R.H., Shegokar R., Keck C.M. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol 2011, 8:207-227.
3. Müller R.H., Radtke M., Wissing S.A. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002, 242:121-128.
4. Muchow M., Maincent P., Muller R.H. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008, 34:1394-1405.
5. Shidhaye S.S., Vaidya R., Sutar S., Patwardhan A., Kadam V.J. Solid lipid nanoparticles and nanostructured lipid carriers--innovative generations of solid lipid carriers. Curr Drug Deliv 2008, 5:324-331.
6. Pardeike J., Hommoss A., Müller R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009, 366:170-184.
7. Strickley R. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004, 21:201-230.
8. Nanjwade B.K., Patel D.J., Udhani R.A., Manvi F.V. Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs. Sci Pharm 2011, 79:705-727.
9. Beloqui A., Solinís M.A., Delgado A., Évora C., del Pozo-Rodríguez A., Rodríguez-Gascón A. Biodistribution of nanostructured lipid carriers (NLCs) after intravenous administration to rats: influence of technological factors. Eur J Pharm Biopharm 2014, 84:309-314.
10. Beloqui A., Solinís M.A., Rodríguez-Gascón A., del Pozo-Rodríguez A. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release 2013, 166:115-123.
11. Lim S.B., Banerjee A., Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release 2012, 163:34-45.
12. Gasco M.R. Lipid nanoparticles: perspectives and challenges. Adv Drug Deliv Rev 2007, 59:377-378.
13. Varshosaz J., Eskandari S., Tabbakhian M. Freeze-drying of nanostructure lipid carriers by different carbohydrate polymers used as cryoprotectants. Carbohydr Polym 2012, 88:1157-1163.
14. Obeidat W.M., Schwabe K., Müller R.H., Keck C.M. Preservation of nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2010, 76:56-67.
15. Abdelwahed W., Degobert G., Stainmesse S., Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 2006, 58:1688-1713.
16. Beloqui A., Solinís M.A., Delgado A., Évora C., Isla A., Rodríguez-Gascón A. Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution. J Microencapsul 2014, 31:1-8.
17. Mehnert W., Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001, 47:165-196.
18. Konan Y.N., Gurny R., Allémann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm 2002, 233:239-252.
19. del Pozo-Rodríguez A., Solinís M.A., Gascón A.R., Pedraz J.L. Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy. Eur J Pharm Biopharm 2009, 71:181-189.
20. Dulieu C., Bazile D. Influence of lipid nanocapsules composition on their aptness to freeze-drying. Pharm Res 2005, 22:285-292.
21. Saliou B., Thomas O., Lautram N., Clavreul A., Hureaux J., Urban T., et al. Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide. Eur J Pharm Sci 2013, 50:172-180.
22. Klang V., Valenta C., Matsko N.B. Electron microscopy of pharmaceutical systems. Micron 2013, 44:45-74.
23. Mittal V., Matsko N.B. Analytical imagining techniques for soft matter characterization 2012, Springer-Verlag, Berlin Heidelberg. 1st ed.
24. Sitterberg J., Ozcetin A., Ehrhardt C., Bakowsky U. Utilising atomic force microscopy for the characterisation of nanoscale drug delivery systems. Eur J Pharm Biopharm 2010, 74:2-13.
25. Bunjes H. Structural properties of solid lipid based colloidal drug delivery systems. Curr Opin Colloid Interface 2011, 16:405-411.
26. Kuntsche J., Horst J.C., Bunjes H. Cryogenic transmission electron microscopy (cryo-TEM) for studying the morphology of colloidal drug delivery systems. Int J Pharm 2011, 417:120-137.
27. Saupe A., Gordon K.C., Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int J Pharm 2006, 314:56-62.
28. Jores K., Mehnert W., Drechsler M., Bunjes H., Johann C., Mäder K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release 2004, 95:217-227.
29. Liu R., Liu Z., Zhang C., Zhang B. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability. J Pharm Sci 2012, 101:3833-3844.
30. Bastiat G., Pritz C.O., Roider C., Fouchet F., Lignières E., Jesacher A., et al. A new tool to ensure the fluorescent dye labeling stability of nanocarriers: a real challenge for fluorescence imaging. J Control Release 2013, 170:334-342.
31. Cork M.J., Danby S.G., Vasilopoulos Y., Hadgraft J., Lane M.E., Moustafa M., et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009, 129:1892-1908.
32. Madison K.C. Barrier function of the skin: "la raison d'être" of the epidermis. J Invest Dermatol 2003, 121:231-241.
33. Raposo S.C., Simões S.D., Almeida A.J., Ribeiro H.M. Advanced systems for glucocorticoids' dermal delivery. Expert Opin Drug Deliv 2013, 10:857-877.
34. Trommer H., Neubert R.H. Overcoming the stratum corneum: the modulation of skin penetration. A review. Skin Pharmacol Physiol 2006, 19:106-121.
35. Patzelt A., Richter H., Knorr F., Schäfer U., Lehr C.M., Dähne L., et al. Selective follicular targeting by modification of the particle sizes. J Control Release 2011, 150:45-48.
36. Müller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002, 54:S131-S155.
37. Muller R.H., Rimpler C., Petersen R., Hommos A., Schwabe K. A new dimension in cosmetic products by nanostructured lipid carriers (NLC) technology. Eurocosmetics 2007, 3:2-7.
38. Souto E.B., Muller R.H., Almeida A.J. Topical delivery of oily actives by means of solid lipid particles. Pharm Technol 2007, 19:28-32.
39. Souto E.B., Almeida A.J., Muller R.H. Nanoparticles (SLN®, NLC®) for cutaneous drug delivery:structure, protection and skin effects. J Biomed Nanotechnol 2007, 3:317-331.
40. Wissing S.A., Müller R.H. Solid lipid nanoparticles (SLN) - a novel carrier for UV blockers. Pharmazie 2001, 56:783-788.
41. Xia Q., Saupe A., Müller R.H., Souto E.B. Nanostructured lipid carriers as novel carrier for sunscreen formulations. Int J Cosmet Sci 2007, 29:473-478.
42. Sivaramakrishnan R., Nakamura C., Mehnert W., Korting H.C., Kramer K.D., Schäfer-Korting M. Glucocorticoid entrapment into lipid carriers - characterisation by parelectric spectroscopy and influence on dermal uptake. J Control Release 2004, 97:493-502.
43. Zhai Y., Zhai G. Advances in lipid-based colloid systems as drug carrier for topic delivery. J Control Release 2014, 193:90-99.
44. Teeranachaideekul V., Boonme P., Souto E.B., Müller R.H., Junyaprasert V.B. Influence of oil content on physicochemical properties and skin distribution of Nile red-loaded NLC. J Control Release 2008, 128:134-141.
45. Vitorino C., Almeida A., Sousa J., Lamarche I., Gobin P., Marchand S., et al. Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: in vitro vs. in vivo studies. Eur J Pharm Biopharm 2014, 86:133-144.
46. Frum Y., Eccleston G.M., Meidan V.M. Factors influencing hydrocortisone permeation into human hair follicles: use of the skin sandwich system. Int J Pharm 2008, 358:144-150.
47. Uprit S., Kumar Sahu R., Roy A., Pare A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J 2013, 21:379-385.
48. Aljuffali I.A., Sung C.T., Shen F.M., Huang C.T., Fang J.Y. Squarticles as a lipid nanocarrier for delivering diphencyprone and minoxidil to hair follicles and human dermal papilla cells. AAPS J 2014, 16:140-150.
49. Shamma R.N., Aburahma M.H. Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. Int J Nanomedicine 2014, 9:5449-5460.
50. Agrawal Y., Petkar K.C., Sawant K.K. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm 2010, 401:93-102.
51. Charoenputtakun P., Pamornpathomkul B., Opanasopit P., Rojanarata T., Ngawhirunpat T. Terpene composited lipid nanoparticles for enhanced dermal delivery of all-trans-retinoic acids. Biol Pharm Bull 2014, 37:1139-1148.
52. Nnamani P.O., Hansen S., Windbergs M., Lehr C.M. Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application. Int J Pharm 2014, 477:208-217.
53. Puglia C., Sarpietro M.G., Bonina F., Castelli F., Zammataro M., Chiechio S. Development, characterization, and in vitro and in vivo evaluation of benzocaine- and lidocaine-loaded nanostructrured lipid carriers. J Pharm Sci 2011, 100:1892-1899.
54. Desai P.R., Shah P.P., Patlolla R.R., Singh M. Dermal microdialysis technique to evaluate the trafficking of surface-modified lipid nanoparticles upon topical application. Pharm Res 2012, 29:2587-2600.
55. Joshi M., Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 2008, 346:124-132.
56. Souto E.B., Wissing S.A., Barbosa C.M., Müller R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004, 278:71-77.
57. Teeranachaideekul V., Müller R.H., Junyaprasert V.B. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC) - effects of formulation parameters on physicochemical stability. Int J Pharm 2007, 340:198-206.
58. Chen S., Liu W., Wan J., Cheng X., Gu C., Zhou H., et al. Preparation of coenzyme Q10 nanostructured lipid carriers for epidermal targeting with high-pressure microfluidics technique. Drug Dev Ind Pharm 2013, 39:20-28.
59. Schwarz J.C., Baisaeng N., Hoppel M., Löw M., Keck C.M., Valenta C. Ultra-small NLC for improved dermal delivery of coenyzme Q10. Int J Pharm 2013, 447:213-217.
60. Stecová J., Mehnert W., Blaschke T., Kleuser B., Sivaramakrishnan R., Zouboulis C.C., et al. Cyproterone acetate loading to lipid nanoparticles for topical acne treatment: particle characterisation and skin uptake. Pharm Res 2007, 24:991-1000.
61. Keshri L., Pathak K. Development of thermodynamically stable nanostructured lipid carrier system using central composite design for zero order permeation of econazole nitrate through epidermis. Pharm Dev Technol 2013, 18:634-644.
62. Gainza G., Pastor M., Aguirre J.J., Villullas S., Pedraz J.L., Hernandez R.M., et al. A novel strategy for the treatment of chronic wounds based on the topical administration of rhEGF-loaded lipid nanoparticles: in vitro bioactivity and in vivo effectiveness in healing-impaired db/db mice. J Control Release 2014, 185:51-61.
63. Gainza G., Bonafonte D.C., Moreno B., Aguirre J.J., Gutierrez F.B., Villullas S., et al. The topical administration of rhEGF-loaded nanostructured lipid carriers (rhEGF-NLC) improves healing in a porcine full-thickness excisional wound model. J Control Release 2015, 197:41-47.
64. Gomes M.J., Martins S., Ferreira D., Segundo M.A., Reis S. Lipid nanoparticles for topical and transdermal application for alopecia treatment: development, physicochemical characterization, and in vitro release and penetration studies. Int J Nanomedicine 2014, 9:1231-1234.
65. Gupta M., Vyas S.P. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem Phys Lipids 2012, 165:454-461.
66. Schwarz J.C., Weixelbaum A., Pagitsch E., Löw M., Resch G.P., Valenta C. Nanocarriers for dermal drug delivery: influence of preparation method, carrier type and rheological properties. Int J Pharm 2012, 437:83-88.
67. Doktorovová S., Araújo J., Garcia M.L., Rakovský E., Souto E.B. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf B: Biointerfaces 2010, 75:538-542.
68. Ricci M., Puglia C., Bonina F., Di Giovanni C., Giovagnoli S., Rossi C. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC): in vitro and in vivo studies. J Pharm Sci 2005, 94:1149-1159.
69. Souto E.B., Müller R.H. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005, 22:501-510.
70. Üner M., Karaman E.F., Aydoğmuş Z. Solid lipid nanoparticles and nanostructured lipid carriers of loratadine for topical application: physicochemical stability and drug penetration through rat skin. Trop J Pharm Res 2014, 13:653-660.
71. Mitri K., Shegokar R., Gohla S., Anselmi C., Müller R.H. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance. Int J Pharm 2011, 414:267-275.
72. Pinto M.F., Moura C.C., Nunes C., Segundo M.A., Costa Lima S.A., Reis S. A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers. Int J Pharm 2014, 477:519-526.
73. Silva A.C., Santos D., Ferreira D.C., Souto E.B. Minoxidil-loaded nanostructured lipid carriers (NLC): characterization and rheological behaviour of topical formulations. Pharmazie 2009, 64:177-182.
74. Sanad R.A., Abdelmalak N.S., Elbayoomy T.S., Badawi A.A. Formulation of a novel oxybenzone-loaded nanostructured lipid carriers (NLCs). AAPS PharmSciTech 2010, 11:1684-1694.
75. Chen-yu G., Chun-fen Y., Qi-lu L., Qi T., Yan-wei X., Wei-na L., et al. Development of a quercetin-loaded nanostructured lipid carrier formulation for topical delivery. Int J Pharm 2012, 430:292-298.
76. Joshi M., Patravale V. Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of valdecoxib. Drug Dev Ind Pharm 2006, 32:911-918.
77. Vitorino C., Almeida J., Gonçalves L.M., Almeida A.J., Sousa J.J., Pais A.A. Co-encapsulating nanostructured lipid carriers for transdermal application: from experimental design to the molecular detail. J Control Release 2013, 167:301-314.
78. Vitorino C., Alves L., Antunes F.E., Sousa J.J., Pais A.A.C.C. Design of a dual nanostructured lipid carrier formulation based on physicochemical, rheological, and mechanical properties. J Nanopart Res 2013, 15:1993-2007.
79. Wang J.J., Liu K.S., Sung K.C., Tsai C.Y., Fang J.Y. Skin permeation of buprenorphine and its ester prodrugs from lipid nanoparticles: lipid emulsion, nanostructured lipid carriers and solid lipid nanoparticles. J Microencapsul 2009, 26:734-747.
80. Bhaskar K., Krishna Mohan C., Lingam M., Jagan Mohan S., Venkateswarlu V., Madhusudan Rao Y., et al. Development of SLN and NLC enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo characteristics. Drug Dev Ind Pharm 2009, 35:98-113.
81. Kawadkar J., Pathak A., Kishore R., Chauhan M.K. Formulation, characterization and in vitro-in vivo evaluation of flurbiprofen-loaded nanostructured lipid carriers for transdermal delivery. Drug Dev Ind Pharm 2013, 39:569-578.
82. Puglia C., Filosa R., Peduto A., de Caprariis P., Rizza L., Bonina F., et al. Evaluation of alternative strategies to optimize ketorolac transdermal delivery. AAPS PharmSciTech 2006, 7:61-69.
83. Gönüllü Ü., Üner M., Yener G., Karaman E.F., Aydoğmuş Z. Formulation and characterization of solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsion of lornoxicam for transdermal delivery. Acta Pharm 2013, 65:1-13.
84. Khurana S., Jain N.K., Bedi P.M. Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam. Life Sci 2013, 93:763-767.
85. Elnaggar Y.S., El-Massik M.A., Abdallah O.Y. Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles. Int J Nanomedicine 2011, 6:3195-3205.
86. Liu Y., Wang L., Zhao Y., He M., Zhang X., Niu M., et al. Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin. Int J Pharm 2014, 476:169-177.
87. Sigurdsson H.H., Kirch J., Lehr C.M. Mucus as a barrier to lipophilic drugs. Int J Pharm 2013, 453:56-64.
88. Beloqui A., Solinís M.A., des Rieux A., Préat V., Rodríguez-Gascón A. Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. Int J Pharm 2014, 468:105-111.
89. Park K. Transport of nanostructured lipid carriers across the intestinal barrier. J Control Release 2013, 166:195.
90. Gaba B., Fazil M., Ali A., Baboota S., Sahni J.K., Ali J. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv 2015, 22:691-700.
91. Iqbal M.A., Md S., Sahni J.K., Baboota S., Dang S., Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 2012, 20:813-830.
92. Zhang T., Chen J., Zhang Y., Shen Q., Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci 2011, 43:174-179.
93. Tran T.H., Ramasamy T., Truong D.H., Choi H.G., Yong C.S., Kim J.O. Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS PharmSciTech 2014, 15:1509-1515.
94. Mandpe L., Pokharkar V. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement. Pharm Dev Technol 2013, 20:320-329.
95. Chen C.C., Tsai T.H., Huang Z.R., Fang J.Y. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 2010, 74:474-482.
96. Mendes A.I., Silva A.C., Catita J.A., Cerqueira F., Gabriel C., Lopes C.M. Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: improving antifungal activity. Colloids Surf B: Biointerfaces 2013, 111:755-763.
97. Patil-Gadhe A., Pokharkar V. Montelukast-loaded nanostructured lipid carriers. Part I: oral bioavailability improvement. Eur J Pharm Biopharm 2014, 88:160-168.
98. Sun M., Nie S., Pan X., Zhang R., Fan Z., Wang S. Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro. Colloids Surf B: Biointerfaces 2014, 113:15-24.
99. Neves A.R., Lúcio M., Martins S., Lima J.L., Reis S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine 2013, 8:177-187.
100. Shangguan M., Lu Y., Qi J., Han J., Tian Z., Xie Y., et al. Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin. J Biomater Appl 2014, 28:887-896.
101. Tiwari R., Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 2011, 415:232-243.
102. Shete H., Chatterjee S., De A., Patravale V. Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int J Pharm 2013, 454:584-592.
103. Shete H.K., Selkar N., Vanage G.R., Patravale V.B. Tamoxifen nanostructured lipid carriers: enhanced in vivo antitumor efficacy with reduced adverse drug effects. Int J Pharm 2014, 468:1-14.
104. Chen Y., Yuan L., Zhou L., Zhang Z.H., Cao W., Wu Q. Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine. Int J Nanomedicine 2012, 7:4581-4591.
105. Zhuang C.Y., Li N., Wang M., Zhang X.N., Pan W.S., Peng J.J., et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 2010, 394:179-185.
106. Ali H., Weigmann B., Neurath M.F., Collnot E.M., Windbergs M., Lehr C.M. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J Control Release 2014, 183:167-177.
107. Beloqui A., Coco R., Alhouayek M., Solinís M., Rodríguez-Gascón A., Muccioli G.G., et al. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. Int J Pharm 2013, 454:775-783.
108. Beloqui A., Coco R., Memvanga P.B., Ucakar B. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int J Pharm 2014, 473:203-212.
109. Landesman-Milo D., Peer D. Altering the immune response with lipid-based nanoparticles. J Control Release 2012, 161:600-608.
110. Schneider H., Braun A., Füllekrug J., Stremmel W., Ehehalt R. Lipid based therapy for ulcerative colitis-modulation of intestinal mucus membrane phospholipids as a tool to influence inflammation. Int J Mol Sci 2010, 11:4149-4164.
111. Ungaro F., Vanbever R. Improving the efficacy of inhaled drugs for severe lung diseases: emerging pulmonary delivery strategies. Adv Drug Deliv Rev 2014, 75:1-2.
112. Andrade F., Rafael D., Videira M., Ferreira D., Sosnik A., Sarmento B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv Drug Deliv Rev 2013, 65:1816-1827.
113. Loira-Pastoriza C., Todoroff J., Vanbever R. Delivery strategies for sustained drug release in the lungs. Adv Drug Deliv Rev 2014, 75:81-91.
114. Cipolla D., Shekunov B., Blanchard J., Hickey A. Lipid-based carriers for pulmonary products: preclinical development and case studies in humans. Adv Drug Deliv Rev 2014, 75:53-80.
115. Weber S., Zimmer A., Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm 2014, 86:7-22.
116. Todoroff J., Vanbever R. Fate of nanomedicines in the lungs. Curr Opin Colloid Interface Sci 2011, 16:246-254.
117. Videira M.A., Botelho M.F., Santos A.C., Gouveia L.F., de Lima J.J., Almeida A.J. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 2002, 10:607-613.
118. Videira M.A., Gano L., Santos C., Neves M., Almeida A.J. Lymphatic uptake of lipid nanoparticles following endotracheal administration. J Microencapsul 2006, 23:855-862.
119. Kardara M., Hatziantoniou S., Sfika A., Vassiliou A.G., Mourelatou E., Muagkou C., et al. Caveolar uptake and endothelial-protective effects of nanostructured lipid carriers in acid aspiration murine acute lung injury. Pharm Res 2013, 30:1836-1847.
120. Patlolla R.R., Chougule M., Patel A.R., Jackson T., Tata P.N., Singh M. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release 2010, 144:233-241.
121. Zhao C., Fan T., Yang Y., Wu M., Li L., Zhou Z., et al. Preparation, macrophages targeting delivery and anti-inflammatory study of pentapeptide grafted nanostructured lipid carriers. Int J Pharm 2013, 450:11-20.
122. Taratula O., Kuzmov A., Shah M., Garbuzenko O.B., Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 2013, 171:349-357.
123. Han Y., Zhang Y., Li D., Chen Y., Sun J., Kong F. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin. Int J Nanomedicine 2014, 9:4107-4116.
124. Pardeike J., Weber S., Haber T., Wagner J., Zarfl H.P., Plank H., et al. Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm 2011, 419:329-338.
125. Pastor M., Moreno-Sastre M., Esquisabel A., Sans E., Viñas M., Bachiller D., et al. Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis. Int J Pharm 2014, 477:485-494.
126. Taratula O., Garbuzenko O.B., Kirkpatrick P., Pandya I., Savla R., Pozharov V.P., et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release 2009, 140:284-293.
127. Saad M., Garbuzenko O.B., Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond) 2008, 3:761-776.
128. Fortunato O., Boeri M., Verri C., Moro M., Sozzi G. Therapeutic use of microRNAs in lung cancer. Biomed Res Int 2014, 2014:1-8.
129. Taratula O., Garbuzenko O.B., Chen A.M., Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target 2011, 19:900-914.
130. Gandhi N.S., Tekade R.K., Chougule M.B. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release 2014, 194:238-256.
131. Merkel O.M., Rubinstein I., Kissel T. siRNA delivery to the lung: what's new?. Adv Drug Deliv Rev 2014, 75:112-128.
132. Selvamuthukumar S., Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis 2012, 11:159.
133. Gomes-da-Silva L.C., Fonseca N.A., Moura V., Pedroso de Lima M.C., Simões S., Moreira J.N. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res 2012, 45:1163-1171.
134. Ozpolat B., Sood A.K., Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev 2014, 66:110-116.
135. Landesman-Milo D., Goldsmith M., Leviatan Ben-Arye S., Witenberg B., Brown E., Leibovitch S., et al. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett 2013, 334:221-227.
136. Diebold Y., Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 2010, 29:596-609.
137. Zarbin M.A., Montemagno C., Leary J.F., Ritch R. Nanomedicine in ophthalmology: the new frontier. Am J Ophthalmol 2010, 150:144-162.
138. Xu Q., Kambhampati S.P., Kannan R.M. Nanotechnology approaches for ocular drug delivery. Middle East Afr J Ophthalmol 2013, 20:26-37.
139. Zarbin M.A., Montemagno C., Leary J.F., Ritch R. Nanotechnology in ophthalmology. Can J Ophthalmol 2010, 45:457-476.
140. Kompella U.B., Amrite A.C., Pacha Ravi R., Durazo S.A. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res 2013, 36:172-198.
141. Kaur I.P., Kakkar S. Nanotherapy for posterior eye diseases. J Control Release 2014, 193:100-112.
142. Khar R.K., Jain G.K., Warsi M.H., Mallick N., Akhter S., Pathan S.A., et al. Nano-vectors for the ocular delivery of nucleic acid-based therapeutics. Indian J Pharm Sci 2010, 72:675-688.
143. Gan L., Wang J., Jiang M., Bartlett H., Ouyang D., Eperjesi F., et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today 2013, 18:290-297.
144. Souto E.B., Doktorovova S., Gonzalez-Mira E., Egea M.A., Garcia M.L. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr Eye Res 2010, 35:537-552.
145. del Pozo-Rodríguez A., Delgado D., Gascón A.R., Solinís M.A. Lipid nanoparticles as drug/gene delivery systems to the retina. J Ocul Pharmacol Ther 2013, 29:173-188.
146. Shen J., Wang Y., Ping Q., Xiao Y., Huang X. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. J Control Release 2009, 137:217-223.
147. Shen J., Deng Y., Jin X., Ping Q., Su Z., Li L. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: improving in vivo ocular distribution. Int J Pharm 2010, 402:248-253.
148. Luo Q., Zhao J., Zhang X., Pan W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011, 403:185-191.
149. Gonzalez-Mira E., Egea M.A., Garcia M.L., Souto E.B. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B: Biointerfaces 2010, 81:412-421.
150. Gonzalez-Mira E., Egea M.A., Souto E.B., Calpena A.C., García M.L. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Nanotechnology 2011, 22:045101.
151. Tian B., Luo Q., Song S., Liu D., Pan H., Zhang W., et al. Novel surface-modified nanostructured lipid carriers with partially deacetylated water-soluble chitosan for efficient ocular delivery. J Pharm Sci 2012, 101:1040-1049.
152. Gonzalez-Mira E., Nikolić S., Calpena A.C., Egea M.A., Souto E.B., García M.L. Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels. J Pharm Sci 2012, 101:707-725.
153. Li X., Nie S.F., Kong J., Li N., Ju C.Y., Pan W.S. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 2008, 363:177-182.
154. Ustündağ-Okur N., Gökçe E.H., Bozbiyik D., Eğrilmez S., Ozer O., Ertan G. Preparation and in vitro-in vivo evaluation of ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitis. Eur J Pharm Sci 2014, 63:204-215.
155. Araújo J., Gonzalez-Mira E., Egea M.A., Garcia M.L., Souto E.B. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm 2010, 393:167-175.
156. Araújo J., Nikolic S., Egea M.A., Souto E.B., Garcia M.L. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf B: Biointerfaces 2011, 88:150-157.
157. Araújo J., Garcia M.L., Mallandrich M., Souto E.B., Calpena A.C. Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. Nanomedicine 2012, 8:1034-1041.
158. Gastaldi L., Battaglia L., Peira E., Chirio D., Muntoni E., Solazzi I., et al. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm 2014, 87:433-444.
159. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001, 47:65-81.
160. Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know?. Adv Drug Deliv Rev 2014, 71:2-14.
161. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010, 37:48-57.
162. Blasi P., Giovagnoli S., Schoubben A., Puglia C., Bonina F., Rossi C., et al. Lipid nanoparticles for brain targeting I. Formulation optimization. Int J Pharm 2011, 419:287-295.
163. Blasi P., Schoubben A., Romano G.V., Giovagnoli S., Di Michele A., Ricci M. Lipid nanoparticles for brain targeting II. Technological characterization. Colloids Surf B: Biointerfaces 2013, 110:130-137.
164. Blasi P., Schoubben A., Traina G., Manfroni G., Barberini L., Alberti P.F., et al. Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity. Int J Pharm 2013, 454:316-323.
165. Esposito E., Mariani P., Ravani L., Contado C., Volta M., Bido S., et al. Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study. Eur J Pharm Biopharm 2012, 80:306-314.
166. Puglia C., Frasca G., Musumeci T., Rizza L., Puglisi G., Bonina F., et al. Curcumin loaded NLC induces histone hypoacetylation in the CNS after intraperitoneal administration in mice. Eur J Pharm Biopharm 2012, 81:288-293.
167. Tsai M.J., Wu P.C., Huang Y.B., Chang J.S., Lin C.L., Tsai Y.H., et al. Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int J Pharm 2012, 423:461-470.
168. Hsu S.H., Wen C.J., Al-Suwayeh S.A., Chang H.W., Yen T.C., Fang J.Y. Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug. Nanotechnology 2010, 21:405101.
169. Kozlovskaya L., Abou-Kaoud M., Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release 2014, 189:133-140.
170. Gabal Y.M., Kamel A.O., Sammour O.A., Elshafeey A.H. Effect of surface charge on the brain delivery of nanostructured lipid carriers in situ gels via the nasal route. Int J Pharm 2014, 473:442-457.
171. Devkar T.B., Tekade A.R., Khandelwal K.R. Surface engineered nanostructured lipid carriers for efficient nose to brain delivery of ondansetron HCl using Delonix regia gum as a natural mucoadhesive polymer. Colloids Surf B: Biointerfaces 2014, 122:143-150.
172. Madane R.G., Mahajan H.S. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Deliv 2015, 14:1-9.
173. Gartziandia O., Herran E., Pedraz J.L., Carro E., Igartua M., Hernandez R.M. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf B: Biointerfaces 2015, 134:304-313.
174. Carbone C., Cupri S., Leonardi A., Puglisi G., Pignatello R. Lipid-based nanocarriers for drug delivery and targeting: a patent survey of methods of production and characterization. Pharm Pat Anal 2013, 2:665-677.
175. Carbone C., Leonardi A., Cupri S., Puglisi G., Pignatello R. Pharmaceutical and biomedical applications of lipid-based nanocarriers. Pharm Pat Anal 2014, 3:199-215.
176. Pardeike J., Schwabe K., Müller R.H. Influence of nanostructured lipid carriers (NLC) on the physical properties of the Cutanova Nanorepair Q10 cream and the in vivo skin hydration effect. Int J Pharm 2010, 396:166-173.